The findings
Creatine is the strongest-graded supplement in this library for women as for men, and the women's trials sharpen the dose: in postmenopausal women the pooled benefit sits at 5 grams a day or more, paired with resistance training, while 3 grams or less without training showed no measurable effect.
Creatine is the rare supplement whose evidence survives the question women actually ask about it, which is not whether it works but whether the trials were run on people like them. Increasingly, they were. The women's literature now has its own pooled analyses, and they say something more specific than the general creatine story: the benefit is real for strength and lean mass, it is paired with resistance training in every trial that finds it, and in postmenopausal women it sits at a dose of 5 grams a day or more, while smaller doses without training showed nothing measurable. Longevity Lab Report grades creatine A- on evidence and A on worth it, at $5 to $10 a month, the strongest grades in this library, and the women's evidence supports them rather than borrowing them.
What the women's trials show
The summit of the current evidence is a 2026 systematic review and meta-analysis of seven randomized trials in 608 postmenopausal women. It found a small increase in lean mass and improved leg press strength with creatine, and it found them under a condition the marketing rarely prints: benefits were evident at 5 grams a day or more combined with resistance training, and trials at 3 grams a day or less without training showed no measurable benefit. The dose and the training are not two separate findings. They are the finding.
In younger women the picture is the general creatine picture, confirmed in female samples. Smith-Ryan and colleagues' 2021 review in Nutrients found supplementation effective for strength and exercise performance in premenopausal women, and a 2025 follow-up review under the same lead author concluded that creatine significantly improved muscle strength and physical function in postmenopausal women. Forbes and colleagues' 2021 meta-analysis in older adults found significant strength improvements against placebo. No serious analysis finds a sex-specific dose: 3 to 5 grams a day of monohydrate is the studied range for everyone, with the postmenopausal pooling suggesting the top of that range, plus training, is where a woman over 50 should aim.
Bone is where the claims outrun the data. The 2026 pooling found no significant improvement in bone mineral density, and a two-year randomized trial in 237 postmenopausal women found the same, with some preservation of bone geometry when creatine was paired with training and walking. Geometry and function signals are worth having, and they are not density. A woman taking creatine for her bones is buying the strength benefit and hoping for the rest.
The dose, stated plainly
| Question | What the trials support |
|---|---|
| Daily dose | 3 to 5 g of creatine monohydrate; 5 g or more in the postmenopausal trials that found benefit |
| Loading | Optional for everyone; saturation arrives in about a month without it |
| Training pairing | Required in the trials that found benefit; doses at 3 g or less without training showed no measurable effect |
| Form | Monohydrate is the studied form; premium forms carry no comparative trial advantage |
The full graded record, including the safety file, the cost basis, and the positions tracked against it, is on the creatine record.
Safety, including the kidney question
Creatine's safety file is the deepest of any supplement in this library, and the women's pages' standard worry has a precise answer. A 2025 systematic review and meta-analysis found that creatine modestly raises serum creatinine, the marker, with no significant change in glomerular filtration rate, the kidney function the marker is supposed to track. Both halves matter: the raised number on a lab report is real, and it is the supplement's own metabolite being measured, not damage being done. Anyone with kidney disease should still talk to their doctor first, because the trials exclude them. Pregnancy and lactation data are thin, and thin data is a reason to wait rather than a finding of harm. The bloating and the bulky-muscle fears that fill the myth pages have no trial behind them at these doses; the scale may move a kilogram or two as muscle holds more water, which is the mechanism working, not fat arriving.
What the experts say
Three verbatim quotes are carried below, each with its source named, from the positions tracked in our expert library.
Rhonda Patrick takes more than the standard dose: "5g is enough to saturate muscles, but around 10g/day benefits brain, bones, and immune system as well." Her position, per our record of her stack, is 10 grams a day of monohydrate, rising when sleep deprived, on emerging brain and bone claims. The trial record supports her muscle dose and not yet her reasons for doubling it: the bone pooling above is null on density, and the cognition claim has a regulatory ceiling, stated below.
Andrew Huberman puts the cognitive threshold at the standard dose: "What is the threshold level of creatine to supplement in order to get the cognitive benefit? [It] appears to be at least five grams per day." His stated basis, per our record of his stack, is cognitive benefit beyond training, especially for people who eat little meat.
Layne Norton speaks to the safety file: "The verdict? Absolutely no evidence of harm." His position cites the 2025 Kreider meta-analysis of more than 250 studies and 26,000 participants, and on the kidney and liver questions the trial record is with him.
One further position is carried in our library without a verbatim quote and is labeled a position: Andy Galpin, who is not among this library's tracked experts, recommends 3 to 5 grams a day with no cycling and calls creatine a lifespan supplement. It agrees with the record and adds nothing the trials do not say.
On cognition, the honest ceiling is regulatory: the European Food Safety Authority's 2024 review could not establish that creatine improves cognitive function. The expert enthusiasm on this page is real, and the pooled trial support for it is not yet, which is exactly the gap this library exists to mark.
Our grade and rationale
Longevity Lab Report grades creatine A- on evidence and A on worth it, at $5 to $10 a month.
The A- rests on the depth and consistency of the strength and lean-mass record, now including women-specific poolings at both life stages, and on a safety file with hundreds of trials behind it. It is not an A because the claims beyond muscle, bone density, cognition, and mood, remain unproven or null in the pooled record, and the grade prices the whole claim set rather than the strongest claim. The A on worth it follows from the arithmetic: the best-evidenced supplement in the library is also one of the cheapest, in the form (plain monohydrate) that every trial used.
The stores statistic, handled carefully
Most women's pages open with the claim that women store 70 to 80 percent less creatine than men. The figure traces to a single 2000 source, Tarnopolsky's work, repeated identically across the review literature and the retail pages until repetition made it look like consensus. It may be roughly right; dietary intake differences between men and women are real, and they point the same way. But a 25-year-old figure repeated is not a measured population fact, and this page does not print it as one. The case for creatine in women does not need it: the trials above were run in women, and they are the argument.
Frequently asked questions
How much creatine should women take? 3 to 5 grams of monohydrate a day. Postmenopausal women should aim at 5 grams and pair it with resistance training, the combination the pooled trials found benefit under.
Will it make me bulky or bloated? No trial at these doses shows either. Muscle holds slightly more water on creatine, which can move the scale a kilogram or two; that is the mechanism, not fat gain.
Is it safe for kidneys? In healthy adults, the pooled record shows creatinine, the marker, rising modestly with no change in actual filtration rate. Kidney disease is a talk-to-your-doctor case because trials exclude it.
Does it help bone density or cognition? Not on current pooled evidence: bone density was null in the 2026 pooling and the two-year trial, and EFSA's 2024 review could not establish a cognitive benefit. Strength, the proven benefit, is itself protective for both over time, but that is an inference, not a trial result.
Limitations: what we do not know
We do not know whether creatine slows bone loss over the decades that matter; the longest women's trial runs two years and reads geometry, not fractures. We do not know whether the cognition claims will survive a properly powered trial; the current record is small studies and a regulatory non-finding. And the premenopausal evidence, while positive, is thinner than the postmenopausal pooling that anchors this page. What would change the grade: a fracture-endpoint bone trial, or a cognition trial large enough to move EFSA's position, in either direction.
Keep reading
The graded record behind every claim on this page is the creatine record, which carries the full trial file, the safety record, and the cost basis. The companion piece on the general evidence, where the experts agree on creatine, covers the muscle and strength record this page draws on for younger women. The three experts quoted above keep their full sourced positions on their own pages: Rhonda Patrick, Andrew Huberman, and Layne Norton.
People mentioned
Supplements mentioned
- CreatineA-
Grades are research summaries, not medical advice. Decisions about your own health belong with your clinician.